miRagen Therapeutics to Participate in Two Investor Conferences in May
April 26 2017 - 7:00AM
Miragen Therapeutics, Inc. (Nasdaq:MGEN), a clinical-stage
biopharmaceutical company focused on the discovery and development
of microRNA-targeted therapies, today announced that William S.
Marshall, Ph.D., President and Chief Executive Officer, will
provide a company overview at the following conferences in May:
- Deutsche Bank 42nd Annual Health Care Conference
- Presentation Date: Wednesday, May 3, 2017
- Presentation Time: 3:30 p.m. ET
- Location: InterContinental Boston
- UBS Global Healthcare Conference
- Presentation Date: Monday, May 22, 2017
- Presentation Time: 1:00 p.m. ET
- Location: Grand Hyatt New York
The presentations will be webcast live and may be
accessed by visiting the "Investors" section of the Company’s web
site at www.investors.miragentherapeutics.com. A replay of the
webcasts will be available for 90 days.
About Miragen Therapeutics,
Inc.
Miragen Therapeutics, Inc. is a clinical-stage
biopharmaceutical company discovering and developing proprietary
RNA-targeted therapeutics with a specific focus on microRNAs and
their role in diseases where there is a high unmet medical
need. miRagen’s two lead product candidates, MRG-106 and
MRG-201, are currently in Phase 1 clinical trials. miRagen’s
clinical product candidate for the treatment of certain cancers,
MRG-106, is an inhibitor of microRNA-155, which is found at
abnormally high levels in several blood cancers. miRagen’s
clinical product candidate for the treatment of pathological
fibrosis, MRG-201, is a replacement for miR-29, which is found at
abnormally low levels in a number of pathological fibrotic
conditions, including cardiac, renal, hepatic, and pulmonary
fibrosis, as well as systemic sclerosis. In addition to
miRagen’s clinical programs, it is developing a pipeline of
pre-clinical product candidates. The goal of miRagen’s
translational medicine strategy is to progress rapidly to first in
human studies once it has established the pharmacokinetics,
pharmacodynamics and safety of the product candidate in
pre-clinical studies. For more information, please visit
www.miragentherapeutics.com.
For information on clinical trials please visit
www.clinicaltrials.gov.
Note Regarding Forward-Looking
Statements
These presentations may contain forward-looking
statements that involve substantial risks and uncertainties for
purposes of the safe harbor provided by the Private Securities
Litigation Reform Act of 1995. All statements contained in these
presentations other than statements of historical fact, including
statements regarding miRagen’s strategy, future operations, future
financial position, future revenue, projected expenses, prospects,
plans and objectives of management are forward-looking statements.
The words “believe,” “may,” “will,” “estimate,” “continue,”
“anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,”
“opportunity,” “goals,” or “should,” and similar expressions are
intended to identify forward-looking statements. Such statements
are based on management’s current expectations and involve risks
and uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements
as a result of many factors, including, without limitation: that
miRagen has incurred losses since its inception, and anticipates
that it will continue to incur significant losses for the
foreseeable future; future financing activities may cause miRagen
to restrict its operations or require it to relinquish rights;
miRagen may fail to demonstrate safety and efficacy of its product
candidates; miRagen’s product candidates are unproven and may never
lead to marketable products; miRagen’s product candidates are based
on a relatively novel technology, which makes it difficult to
predict the time and cost of development and of subsequently
obtaining regulatory approval, if at all; and miRagen’s product
candidates may cause undesirable side effects or have other
properties that could delay or prevent the regulatory approval.
miRagen has based these forward-looking statements
largely on its current expectations and projections about future
events and trends. These forward-looking statements are subject to
a number of risks, uncertainties and assumptions, including those
described in under the heading “Risk Factors” in miRagen’s Annual
Report on Form 10-K and subsequent periodic reports filed with the
Securities and Exchange Commission. Moreover, miRagen operates in a
very competitive and rapidly changing environment. New risks emerge
from time to time. It is not possible for its management to predict
all risks, nor can it assess the impact of all factors on its
business or the extent to which any factor, or combination of
factors, may cause actual results to differ materially from those
contained in any forward-looking statements it may make. In light
of these risks, uncertainties and assumptions, the future events
and trends discussed in the presentations may not occur and actual
results could differ materially and adversely from those
anticipated or implied in the forward-looking statements. miRagen
undertakes no obligation to revise or publicly release the results
of any revision to such forward-looking statements, except as
required by law. Given these risks and uncertainties, readers are
cautioned not to place undue reliance on such forward-looking
statements. All forward-looking statements are qualified in their
entirety by this cautionary statement.
miRagen Investor Contact:
Adam Levy
Chief Business Officer
(720) 407-4595
alevy@miragenrx.com
Miragen Therapeutics (NASDAQ:MGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Miragen Therapeutics (NASDAQ:MGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024